Literature DB >> 21590401

Vector characterization methods for quality control testing of recombinant adeno-associated viruses.

J Fraser Wright1, Olga Zelenaia.   

Abstract

Adeno-associated virus (AAV)-based vectors expressing therapeutic gene products have shown great promise for human gene therapy. A major challenge for translation of promising research to clinical development is the establishment of appropriate quality control (QC) test methods to characterize clinical grade AAV vectors. This chapter focuses on QC testing, providing an overview of characterization methods appropriate for clinical vectors prepared for early phase clinical studies, and detailed descriptions for selected assays that are useful to assess AAV vector safety, potency, and purity.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21590401     DOI: 10.1007/978-1-61779-095-9_11

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  11 in total

Review 1.  Progress and challenges in viral vector manufacturing.

Authors:  Johannes C M van der Loo; J Fraser Wright
Journal:  Hum Mol Genet       Date:  2015-10-30       Impact factor: 6.150

2.  In vivo genome editing of the albumin locus as a platform for protein replacement therapy.

Authors:  Rajiv Sharma; Xavier M Anguela; Yannick Doyon; Thomas Wechsler; Russell C DeKelver; Scott Sproul; David E Paschon; Jeffrey C Miller; Robert J Davidson; David Shivak; Shangzhen Zhou; Julianne Rieders; Philip D Gregory; Michael C Holmes; Edward J Rebar; Katherine A High
Journal:  Blood       Date:  2015-08-21       Impact factor: 22.113

3.  Preclinical evaluation of an anti-HCV miRNA cluster for treatment of HCV infection.

Authors:  Xiao Yang; Katherine Marcucci; Xavier Anguela; Linda B Couto
Journal:  Mol Ther       Date:  2013-01-08       Impact factor: 11.454

4.  CD8+ T cell recognition of epitopes within the capsid of adeno-associated virus 8-based gene transfer vectors depends on vectors' genome.

Authors:  Te-Lang Wu; Hua Li; Susan M Faust; Emily Chi; Shangzhen Zhou; Fraser Wright; Katherine A High; Hildegund C J Ertl
Journal:  Mol Ther       Date:  2013-09-30       Impact factor: 11.454

5.  Robust ZFN-mediated genome editing in adult hemophilic mice.

Authors:  Xavier M Anguela; Rajiv Sharma; Yannick Doyon; Jeffrey C Miller; Hojun Li; Virginia Haurigot; Michelle E Rohde; Sunnie Y Wong; Robert J Davidson; Shangzhen Zhou; Philip D Gregory; Michael C Holmes; Katherine A High
Journal:  Blood       Date:  2013-10-01       Impact factor: 22.113

6.  ZFN-mediated in vivo gene editing in hepatocytes leads to supraphysiologic α-Gal A activity and effective substrate reduction in Fabry mice.

Authors:  Silvere Pagant; Marshall W Huston; Luciana Moreira; Lin Gan; Susan St Martin; Scott Sproul; Michael C Holmes; Kathleen Meyer; Thomas Wechsler; Robert J Desnick; Makiko Yasuda
Journal:  Mol Ther       Date:  2021-03-26       Impact factor: 11.454

Review 7.  Translating CRISPR-Cas Therapeutics: Approaches and Challenges.

Authors:  Lavina Sierra Tay; Nathan Palmer; Rebecca Panwala; Wei Leong Chew; Prashant Mali
Journal:  CRISPR J       Date:  2020-08

Review 8.  Pharmacology of Recombinant Adeno-associated Virus Production.

Authors:  Magalie Penaud-Budloo; Achille François; Nathalie Clément; Eduard Ayuso
Journal:  Mol Ther Methods Clin Dev       Date:  2018-01-08       Impact factor: 6.698

Review 9.  Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays.

Authors:  Thilo M Buck; Jan Wijnholds
Journal:  Int J Mol Sci       Date:  2020-06-12       Impact factor: 5.923

10.  Advanced Characterization of DNA Molecules in rAAV Vector Preparations by Single-stranded Virus Next-generation Sequencing.

Authors:  Emilie Lecomte; Benoît Tournaire; Benjamin Cogné; Jean-Baptiste Dupont; Pierre Lindenbaum; Mélanie Martin-Fontaine; Frédéric Broucque; Cécile Robin; Matthias Hebben; Otto-Wilhelm Merten; Véronique Blouin; Achille François; Richard Redon; Philippe Moullier; Adrien Léger
Journal:  Mol Ther Nucleic Acids       Date:  2015-10-27       Impact factor: 10.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.